Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, Zeng Q, Fazli L, Rennie PS, Mills IG, Danielsen H, Theis F, Patterson JB, Jin Y, Saatcioglu F(2024) Author Correction: IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling Nat Commun, 15(1), 6190 DOI 10.1038/s41467-024-50645-x, PubMed 39043728
Bretthauer M, Pilonis ND(2024) Brief sigmoidoscopy provides 21-year colorectal cancer risk reduction in men Lancet Gastroenterol Hepatol(in press) DOI 10.1016/S2468-1253(24)00199-7, PubMed 39038481
Amstutz A, Schönenberger CM, Speich B, Griessbach A, Schwenke JM, Glasstetter J, James S, Verkooijen HM, Nickolls B, Relton C, Hemkens LG, Chammartin F, Gerber F, Labhardt ND, Schandelmaier S, Briel M(2024) Characteristics, consent patterns, and challenges of randomized trials using the Trials within Cohorts (TwiCs) design A scoping review J Clin Epidemiol, 111469(in press) DOI 10.1016/j.jclinepi.2024.111469, PubMed 39032590